| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Carsten Wrenger | Q48017234 |
| Henning Ulrich | Q50419702 | ||
| P2093 | author name string | Edmarcia Elisa de Souza | |
| Claudiana Lameu | |||
| Micheli Mainardi Pillat | |||
| Arne Krüger | |||
| Lara Mendes Ferreira Guimarães | |||
| P2860 | cites work | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro | Q84360011 |
| Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies | Q86824600 | ||
| Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2 | Q87726414 | ||
| Of chloroquine and COVID-19 | Q87843165 | ||
| Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate | Q22061950 | ||
| Chloroquine is a potent inhibitor of SARS coronavirus infection and spread | Q24815979 | ||
| Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines | Q28255917 | ||
| The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites | Q28480979 | ||
| Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance | Q29615118 | ||
| Acute respiratory distress syndrome: the Berlin Definition | Q29615138 | ||
| Chloroquine transport via the malaria parasite's chloroquine resistance transporter | Q30041673 | ||
| Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection | Q30419612 | ||
| A molecular marker for chloroquine-resistant falciparum malaria | Q31921233 | ||
| Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture | Q33747584 | ||
| Effects of chloroquine on viral infections: an old drug against today's diseases? | Q33973620 | ||
| The intracellular trafficking pathway of transferrin | Q34038954 | ||
| Chloroquine-resistant malaria | Q34087800 | ||
| Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors | Q34582501 | ||
| HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes | Q34637857 | ||
| Angiotensin II and nitric oxide interaction. | Q34963306 | ||
| Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs | Q35669039 | ||
| Angiotensin-converting enzyme-2: a molecular and cellular perspective | Q35953162 | ||
| Angiotensin II revisited: new roles in inflammation, immunology and aging | Q36039299 | ||
| pfcrt is more than the Plasmodium falciparum chloroquine resistance gene: a functional and evolutionary perspective | Q36113546 | ||
| Contribution of the pfmdr1 gene to antimalarial drug-resistance | Q36117630 | ||
| Antimalarial drugs inhibiting hemozoin (beta-hematin) formation: a mechanistic update | Q36678059 | ||
| From mitochondria to disease: role of the renin-angiotensin system | Q36929305 | ||
| ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis | Q36929414 | ||
| Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine | Q37190763 | ||
| Corticosteroids block autophagy protein recruitment in Aspergillus fumigatus phagosomes via targeting dectin-1/Syk kinase signaling | Q37442775 | ||
| Quinolines and structurally related heterocycles as antimalarials | Q37751449 | ||
| Antimalarial drugs: modes of action and mechanisms of parasite resistance | Q37820670 | ||
| Hydroxychloroquine: from malaria to autoimmunity | Q37827403 | ||
| Neutrophil to lymphocyte ratio and cardiovascular diseases: a review | Q38069191 | ||
| Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities | Q38099027 | ||
| Angiotensin-(1-7) and angiotensin-(1-9): function in cardiac and vascular remodelling | Q38193206 | ||
| Role of Different Pfcrt and Pfmdr-1 Mutations in Conferring Resistance to Antimalaria Drugs in Plasmodium falciparum. | Q38288177 | ||
| Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease | Q38809095 | ||
| New insights into the elucidation of angiotensin-(1-7) in vivo antiarrhythmic effects and its related cellular mechanisms | Q39300324 | ||
| Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases | Q39360987 | ||
| Evaluating nanoparticle sensor design for intracellular pH measurements. | Q39735460 | ||
| Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2. | Q39972263 | ||
| SARS coronavirus 7a protein blocks cell cycle progression at G0/G1 phase via the cyclin D3/pRb pathway | Q40348548 | ||
| A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome | Q41592036 | ||
| Targeting autophagy in cancer | Q41912265 | ||
| In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine | Q41913526 | ||
| Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy | Q41914228 | ||
| Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate | Q41921033 | ||
| Angiotensin (1-7) prevent heart dysfunction and left ventricular remodeling caused by renal dysfunction in 5/6 nephrectomy mice | Q46072583 | ||
| New insights into the antiviral effects of chloroquine. | Q46913485 | ||
| Potential role of Plasmodium falciparum exported protein 1 in the chloroquine mode of action | Q48021672 | ||
| A convenient cell fusion assay for the study of SARS-CoV entry and inhibition | Q50718881 | ||
| Palmitoylation of the cysteine-rich endodomain of the SARS-coronavirus spike glycoprotein is important for spike-mediated cell fusion. | Q53585772 | ||
| Levels of chloroquine resistance in Plasmodium falciparum are determined by loci other than pfcrt and pfmdr1. | Q53981724 | ||
| Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion | Q63865766 | ||
| Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS | Q79218330 | ||
| Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial | Q87908797 | ||
| Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 | Q87949688 | ||
| SARS-CoV-2, the Virus that Causes COVID-19: Cytometry and the New Challenge for Global Health | Q88489983 | ||
| The depressor axis of the renin-angiotensin system and brain disorders: a translational approach | Q88867167 | ||
| A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension | Q89107689 | ||
| Ruxolitinib Regulates the Autophagy Machinery in Multiple Myeloma Cells | Q89751523 | ||
| Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study | Q89916821 | ||
| Dysregulation of immune response in patients with COVID-19 in Wuhan, China | Q90251434 | ||
| New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? | Q90327245 | ||
| Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis | Q90367369 | ||
| Antiretroviral-Mediated Microglial Activation Involves Dysregulated Autophagy and Lysosomal Dysfunction | Q90381414 | ||
| Insights from nanomedicine into chloroquine efficacy against COVID-19 | Q90591389 | ||
| Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV | Q90713511 | ||
| Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 | Q90744915 | ||
| Chemical Proteomics and Super-resolution Imaging Reveal That Chloroquine Interacts with Plasmodium falciparum Multidrug Resistance-Associated Protein and Lipids | Q91404792 | ||
| Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic | Q91556054 | ||
| Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System | Q91703665 | ||
| Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 | Q91864250 | ||
| COVID-19: risk for cytokine targeting in chronic inflammatory diseases? | Q91971418 | ||
| CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement | Q92053974 | ||
| T regulatory cells activation and distribution are modified in critically ill patients with acute respiratory distress syndrome: A prospective single-centre observational study | Q92369802 | ||
| Bi-directional differentiation of single bronchioalveolar stem cells during lung repair | Q92619966 | ||
| The Use of Antimalarial Drugs against Viral Infection | Q92633499 | ||
| Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial | Q93207522 | ||
| A human monoclonal antibody blocking SARS-CoV-2 infection | Q94440473 | ||
| High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients | Q94452375 | ||
| Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State | Q94553295 | ||
| A glimpse into the eye of the COVID-19 cytokine storm | Q94595166 | ||
| A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 | Q96122302 | ||
| Immunology of COVID-19: Current State of the Science | Q96156437 | ||
| Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective | Q96163477 | ||
| Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal | Q100702007 | ||
| P921 | main subject | chloroquine | Q422438 |
| antimalarial | Q521616 | ||
| COVID-19 | Q84263196 | ||
| P577 | publication date | 2020-07-19 | |
| 2020-09-01 | |||
| P1433 | published in | Cytometry Part A | Q15764023 |
| P1476 | title | Insights in chloroquine action: perspectives and implications in Malaria and COVID-19 |
| Q104486623 | Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology | cites work | P2860 |
Search more.